MahanimbineCAS# 21104-28-9 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 21104-28-9 | SDF | Download SDF |
| PubChem ID | 167963 | Appearance | White powder |
| Formula | C23H25NO | M.Wt | 331.5 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in chloroform | ||
| Chemical Name | 3,5-dimethyl-3-(4-methylpent-3-enyl)-11H-pyrano[3,2-a]carbazole | ||
| SMILES | CC1=C2C(=C3C(=C1)C4=CC=CC=C4N3)C=CC(O2)(C)CCC=C(C)C | ||
| Standard InChIKey | HTNVFUBCWIYPJN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H25NO/c1-15(2)8-7-12-23(4)13-11-18-21-19(14-16(3)22(18)25-23)17-9-5-6-10-20(17)24-21/h5-6,8-11,13-14,24H,7,12H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Mahanimbine inhibits AChE activity in a dose-dependent manner. 2. Mahanimbine and mangiferin increases the glucose utilization in a dose-dependent manner, can prevent obesity and use in management of diabetes. 3. Mahanimbine can prevent high-fat diet (HFD)-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress. 4. Mahanimbine can lower the absorption of dietary fat resulting in dietary fat excretion. |
| Targets | AChR |
Mahanimbine Dilution Calculator
Mahanimbine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0166 mL | 15.083 mL | 30.1659 mL | 60.3318 mL | 75.4148 mL |
| 5 mM | 0.6033 mL | 3.0166 mL | 6.0332 mL | 12.0664 mL | 15.083 mL |
| 10 mM | 0.3017 mL | 1.5083 mL | 3.0166 mL | 6.0332 mL | 7.5415 mL |
| 50 mM | 0.0603 mL | 0.3017 mL | 0.6033 mL | 1.2066 mL | 1.5083 mL |
| 100 mM | 0.0302 mL | 0.1508 mL | 0.3017 mL | 0.6033 mL | 0.7541 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- BMY 7378
Catalog No.:BCC5063
CAS No.:21102-95-4
- CART (62-76) (rat, human)
Catalog No.:BCC6008
CAS No.:210978-19-1
- W-84 dibromide
Catalog No.:BCC6682
CAS No.:21093-51-6
- Org 12962 hydrochloride
Catalog No.:BCC7718
CAS No.:210821-63-9
- Sakakin
Catalog No.:BCN4916
CAS No.:21082-33-7
- CP 471474
Catalog No.:BCC2373
CAS No.:210755-45-6
- 7,8-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8290
CAS No.:2107-77-9
- 5,7-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8284
CAS No.:2107-76-8
- PD 168568 dihydrochloride
Catalog No.:BCC7702
CAS No.:210688-56-5
- 6alpha-Hydroxylycopodine
Catalog No.:BCN7403
CAS No.:21061-92-7
- 1,11b-Dihydro-11b-hydroxymaackiain
Catalog No.:BCN3914
CAS No.:210537-05-6
- 1,11b-Dihydro-11b-hydroxymedicarpin
Catalog No.:BCN3913
CAS No.:210537-04-5
- SB 265610
Catalog No.:BCC5936
CAS No.:211096-49-0
- Marsformoxide B
Catalog No.:BCN6687
CAS No.:2111-46-8
- Sobetirome
Catalog No.:BCC1957
CAS No.:211110-63-3
- Rubranol
Catalog No.:BCN4917
CAS No.:211126-61-3
- 9,17-Octadecadiene-12,14-diyne-1,11,16-triol
Catalog No.:BCN1497
CAS No.:211238-60-7
- m-Chlorophenylbiguanide hydrochloride
Catalog No.:BCC6650
CAS No.:2113-05-5
- R18
Catalog No.:BCC2383
CAS No.:211364-78-2
- Astrocasine
Catalog No.:BCN2150
CAS No.:2114-92-3
- Dendrobine
Catalog No.:BCN5923
CAS No.:2115-91-5
- Dalcetrapib (JTT-705, RO4607381)
Catalog No.:BCC2328
CAS No.:211513-37-0
- WHI-P154
Catalog No.:BCC2202
CAS No.:211555-04-3
- WHI-P97
Catalog No.:BCC2056
CAS No.:211555-05-4
Effect of Mangiferin and Mahanimbine on Glucose Utilization in 3T3-L1 cells.[Pubmed:23661997]
Pharmacogn Mag. 2013 Jan;9(33):72-5.
BACKGROUND: Stem barks of Mangifera indica contain a rich content of mangiferin (xanthone glucoside), whereas Murraya koenigii leaves contain rich sources of Mahanimbine (carbazole alkaloid) and used traditionally for the treatment of diabetes. OBJECTIVE: To investigate the effects of mangiferin (xanthone glucoside) and Mahanimbine (carbazole alkaloid) on glucose utilization in 3T3-L1 cells. MATERIALS AND METHODS: Mangiferin was isolated from stem barks of Mangifera indica and Mahanimbine was isolated from Murraya koenigii leaves. These isolated compounds were subjected to MTT assay and glucose utilization test with 3T3-L1 cells. RESULTS: Treatment of the 3T3-L1 cells with mangiferin and Mahanimbine increased the glucose utilization in a dose-dependent manner. At a concentration of 1 mM, mangniferin showed 2-fold increase in glucose utilization compared with untreated control. In case of Mahanimbine, the observed effect at 1 mM was almost equivalent to positive control (insulin at 1 muM). Moreover, MTT assay showed that both of these compounds were less toxic at a concentration of 1 mM (nearly 75% cells are viable). CONCLUSION: The present results indicated that these natural products (mangiferin and Mahanimbine) exhibited potential ethnomedical uses in management of diabetes.
Acetylcholinesterase inhibitory potential of a carbazole alkaloid, mahanimbine, from Murraya koenigii.[Pubmed:19943242]
Phytother Res. 2010 Apr;24(4):629-31.
In the search for acetylcholinesterase (AChE) inhibitors from Indian medicinal plants, via bioassay-guided isolation, a carbazole alkaloid, Mahanimbine [3, 5-dimethyl-3-(4- methylpent-3-enyl)-11H-pyrano [5, 6-a] carbazole], was isolated from the petroleum ether extract of the leaves of Murraya koenigii. Inhibition of AChE was evaluated based on Ellman's method using 96-well microplate readers. Mahanimbine inhibited AChE activity in a dose-dependent manner with an IC(50) value of 0.03 +/- 0.09 mg/mL, while galantamine was used as a standard. The AChE inhibitory activity of this carbazole alkaloid has not been reported so far, and this study is the first to reveal this activity in carbazole alkaloid Mahanimbine, isolated from Murraya koenigii.
Antiobesity and lipid lowering effects of Murraya koenigii (L.) Spreng leaves extracts and mahanimbine on high fat diet induced obese rats.[Pubmed:20655993]
Fitoterapia. 2010 Dec;81(8):1129-33.
The dichloromethane (MKD) and ethyl acetate (MKE) extracts of Murraya koenigii leaves significantly reduced the body weight gain, plasma total cholesterol (TC) and triglyceride (TG) levels significantly when given orally at a dose of 300 mg/kg/day to the high fat diet (HFD) induced obese rats for 2 weeks. The observed antiobesity and antihyperlipidemic activities of these extract are correlated with the carbazole alkaloids present in them. Mahanimbine (1) when given orally (30 mg/kg/day) also significantly lowered the body weight gain as well as plasma TC and TG levels. These findings demonstrate the excellent pharmacological potential of Mahanimbine to prevent obesity.
Effect of mahanimbine, an alkaloid from curry leaves, on high-fat diet-induced adiposity, insulin resistance, and inflammatory alterations.[Pubmed:27663177]
Biofactors. 2017 Mar;43(2):220-231.
Spices and condiments, small but an integral part of the daily diet, are known to affect physiological functions. This study evaluated the effects of Mahanimbine, a major carbazole alkaloid from Murraya koenigii (curry leaves), against progression of high-fat diet (HFD)-induced metabolic complications in mice (male and female). Mahanimbine at 2 mg/kg (HFD + LD) and 4 mg/kg (HFD + HD) of body weight was administered daily along with HFD feeding for 12 weeks. At the end of the study, male HFD + LD and HFD + HD groups showed 51.70 +/- 3.59% and 47.37 +/- 3.73% weight gain, respectively, as compared with 71.02 +/- 6.04% in HFD fed mice whereas female HFD + LD and HFD + HD groups showed 24.31 +/- 1.68% and 25.10 +/- 2.61% weight gain as compared with HFD group with 36.69 +/- 3.60% of weight gain. Mahanimbine prevented HFD-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress. Moreover, Mahanimbine treatment improved glucose clearance and upregulated the expression of insulin responsive genes in liver and adipose tissue. Male and female mice showed different traits in development of HFD-induced metabolic disturbances; however, Mahanimbine treatment exerted similar effects in both the sexes. In addition, Mahanimbine lowered the absorption of dietary fat resulting in dietary fat excretion. In conclusion, daily consumption of Mahanimbine and thereby curry leaves may alleviate development of HFD-induced metabolic alterations. (c) 2016 BioFactors, 43(2):220-231, 2017.
